Jeffrey S. Buguliskis Ph.D. Technical Editor Genetic Engineering & Biotechnology News

Listen in to a conversation with three members of the Illuminating the Druggable Genome (IDG) Consortium: Larry Sklar, Ph.D., chair in cancer drug discovery and director of the University of New Mexico’s Center for Molecular Discovery, Avi Ma'ayan, Ph.D., director of the Mount Sinai Center for Bioinformatics and professor in the department of pharmacological sciences, and Bryan Roth, M.D., Ph.D., Director, National Institute of Mental Health’s (NIMH) psychoactive  drug screening program and professor of protein therapeutics and translational proteomics at the University of North Carolina, Chapel Hill. The investigators discuss some of the history surrounding the IDG program’s start, how they got involved, and what they foresee in the druggable genome’s future.

Previous articleVIDEO: Pharos – A Lighthouse for Navigating the Dark Genome
Next articleVancomycin Modified to Combat Growing Antibiotic Resistance Threat